Sectors

Pfizer Ventures joined Mission’s other existing investors to push the mitochondria-focused drug developer’s lifetime funding to approximately $143m.

Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.

Amgen-backed immuno-oncology spinout Immatics has gone public through a reverse merger with special purpose acquisition company Arya Sciences.

Novo, GSK and Amgen-backed NK oncology therapy developer Nkarta Therapeutics has set a range that will net it between $140m and $160m.

Celgene is set for an exit having invested $17m in small molecule cancer drug developer Nurix Therapeutics five years ago.

UCSF has unveiled Nine Square Therapeutics with $50m in series A capital from founding investor Apple Tree Partners.

The ultrasound therapeutics developer, a University of Oxford spinout, has raised series B2 funding in the run-up to clinical testing of its cancer drug delivery platform.

Novo and Sanofi are among the investors that could exit the mineralisation disease therapy developer, which has filed to raise up to $86.3m.

Pfizer Ventures joined Mission’s other existing investors to push the mitochondria-focused drug developer’s lifetime funding to approximately $143m.

The GLP-backed international logistics provider raised $71.1m in a Taikang-led round that will support a global expansion.

BRI Ventures was part of a consortium that provided $53m for mobile wallet developer Payfazz, which also counts Telkom Indonesia as an investor.